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Abstract
Taurine (aminoethane sulfonic acid) is an ubiquitous compound, found in very high concentrations in heart and
muscle. Although taurine is classified as an amino acid, it does not participate in peptide bond formation. Nonetheless,
the amino group of taurine is involved in a number of important conjugation reactions as well as in the scavenging of
hypochlorous acid. Because taurine is a fairly inert compound, it is an ideal modulator of basic processes, such as
osmotic pressure, cation homeostasis, enzyme activity, receptor regulation, cell development and cell signalling. The
present review discusses several physiological functions of taurine. First, the observation that taurine depletion leads to
the development of a cardiomyopathy indicates a role for taurine in the maintenance of normal contractile function.
Evidence is provided that this function of taurine is mediated by changes in the activity of key Ca
2+ transporters and
the modulation Ca
2+ sensitivity of the myofibrils. Second, in some species, taurine is an established osmoregulator,
however, in mammalian heart the osmoregulatory function of taurine has recently been questioned. Third, taurine
functions as an indirect regulator of oxidative stress. Although this action of taurine has been widely discussed, its
mechanism of action is unclear. A potential mechanism for the antioxidant activity of taurine is discussed. Fourth,
taurine stabilizes membranes through direct interactions with phospholipids. However, its inhibition of the enzyme,
phospholipid N-methyltransferase, alters the phosphatidylcholine and phosphatidylethanolamine content of
membranes, which in turn affects the function of key proteins within the membrane. Finally, taurine serves as a
modulator of protein kinases and phosphatases within the cardiomyocyte. The mechanism of this action has not been
studied. Taurine is a chemically simple compound, but it has profound effects on cells. This has led to the suggestion
that taurine is an essential or semi-essential nutrient for many mammals.
Introduction
Taurine is an ubiquitous sulfur-containing, b-amino
acid, which is considered an essential nutrient in some
species [1]. Although it is found in high concentration
in most mammalian tissues, its concentration is particu-
larly high in cardiac and skeletal muscle. Lubec et al. [2]
have shown that taurine slowly accumulates in the heart
following intravenous administration but once taken up
by the heart it turns over very slowly. Myocardial taur-
ine content is species dependent, with levels varying
from ~1.8 µg/g wet wt in the frog to ~39.4 µg/g wet wt
in the mouse [3]. According to Kocsis et al. [3], a corre-
lation exists between taurine levels and heart rate, with
the highest taurine levels found in species with the
highest heart rates. Moreover, a transmural gradient of
taurine exists in the left ventricle, with the highest taur-
ine concentrations found in the endocardium, which
experiences the greatest work load. Based on this evi-
dence alone Kocsis et al. [3] suggested that taurine
might be linked through some mechanism to the work-
load of the heart.
A considerable body of evidence has been gathered on
the pharmacological actions of taurine. These studies
have largely focused on the cytoprotective activity of
taurine. However, they provide little information on the
physiological actions of taurine. Until recently, the phy-
siological actions of taurine were studied using a model
of taurine depletion mediated by taurine transport inhi-
bitors or a model of nutritional depletion in cats.
Although these studies have uncovered new actions of
taurine, in the case of the transport inhibitors it is
unclear if the reported actions are related to taurine
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any medium, provided the original work is properly cited.depletion per se or the side effects of the transport inhi-
bitors. The recent development of taurine transporter
knockout models has facilitated the study of taurine
deficiency in rodents and has dramatically improved the
chances of definitively establishing the key physiological
functions of taurine. The present review discusses the
physiological roles of taurine in heart and skeletal mus-
cle, focusing on the maintenance of contractile function,
osmoregulation, conjugation, antioxidant activity, mem-
brane stabilization and protein phosphorylation.
Chemical reactions involving taurine
Taurine was once considered an end product of sulfur
amino acid metabolism, a presumption based on the +4
oxidation state of the sulfur (present as a sulfonic acid
moiety). Although it has been suggested that taurine can
serve as an antioxidant, the sulfonic acid is incapable of
scavenging the common oxidants, namely, superoxide,
hydrogen peroxide and hydroxyl radical. Nonetheless,
the amino group of taurine can neutralize hypochlorous
acid, one of the reactive species generated by neutro-
phils. In that reaction, taurine is converted to taurine
chloramine, which is less toxic than hypochlorous acid
and serves as a modulator of the immune system [4].
The amino group of taurine is commonly involved in
conjugation reactions. One potentially important reac-
tion is the interaction of taurine with uridine to form 5-
taurinomethyluridine, a modified base located in the
wobble position of some mitochondrial t-RNAs [5,6].
This reaction has attracted considerable attention
because of its potential involvement in the regulation of
mitochondrial protein synthesis [7,8]. Other taurine-
associated conjugation reactions play central roles in the
elimination of toxins from the body [9], the metabolism
of lipids (via bile acid conjugation) [10] and the activity
of glycolipids [11]. However, the relative chemical inac-
tivity of taurine makes the b-amino acid attractive as a
modulator of basic processes, such as osmotic pressure,
cation homeostasis, enzyme activity, receptor regulation,
cell development and cell signaling.
Is taurine required for normal contractile function of the
heart and muscle?
Several species, among them cats, dogs and foxes,
develop cardiomyopathies when maintained on a taurine
deficient diet [12-14]. The original report attributing the
development of a cardiomyopathy in cats to taurine
deficiency was published in 1987 by Pion et al. [12].
Unlike most dilated cardiomyopathies, Pion et al. [12]
found that the taurine deficient cardiomyopathy was
reversible, responding favorably to taurine supplementa-
tion. Echocardiographic analysis revealed that the taur-
ine deficient cardiomyopathy was characterized by
reduced fractional shortening combined with an increase
in left ventricular chamber dimensions and impaired
response to dobutamine [15,16]. Novotny et al. [17] also
found decreases in the rate of pressure rise (+dP/dt, a
measure of contractility), reductions in the rate of pres-
sure decline (-dP/dt, a measure of relaxation) and
increases in ventricular chamber compliance in the taur-
ine deficient heart of cats, suggesting that the taurine
deficient heart is characterized by defects in both systo-
lic and diastolic function. Also supporting the existence
of a taurine deficient cardiomyopathy was the finding
that rodents, which can readily synthesize taurine in the
liver, develop a taurine deficient cardiomyopathy when
the taurine transporter is genetically abolished [18].
Although the mechanism underlying the development
of the taurine deficient cardiomyopathy has not been
established, it is generally accepted that heart failure is
characterized by impaired contraction arising from one
or more of the following conditions: (a) diminished
handling of calcium by the heart, (b) impaired calcium
sensitivity of the contractile proteins, (c) loss of cardio-
myocytes and (d) insufficient ATP to drive contraction.
Several of these conditions are taurine dependent.
The regulation of calcium homeostasis by taurine has
been extensively studied [19,20] although many of the
studies examined the effect of extracellular taurine on
both contractile function and [Ca
2+]i[21-24]. Using a
skinned fiber preparation containing permeabilized cell
membrane, Steele et al. [25] and Galler et al. [26] pro-
vided the first evidence that physiological concentrations
of taurine can increase Ca
2+ sensitivity of contractile pro-
teins and alter tension development. These effects of
taurine were attributed to the modulation of sarcoplas-
mic reticular Ca
2+ release, with the effect greater in pre-
parations containing Ca
2+ deficient sarcoplasmic
reticulum, but less when the sarcoplasmic reticulum con-
tain a high Ca
2+ load. In contrast, acute taurine elevations
exert no apparent effect on Ca
2+ uptake by enriched sar-
coplasmic reticular preparations [27-29]. However, the
acute taurine studies do not rule out a role of the sarco-
plasmic reticular Ca
2+ pump in the chronic actions of
taurine. Indeed, in vivo chronic taurine influences the
activity of the sarcoplasmic reticular Ca
2+ ATPase
through at least two factors that are altered by taurine.
First, recent evidence reveals that the phosphorylation of
the sarcoplasmic reticular phosphoprotein, phospholam-
ban is reduced in the taurine deficient heart [30]. Because
the phosphorylation of phospholamban enhances the rate
of Ca
2+ uptake by the sarcoplasmic reticulum, it increases
the rate of myocardial relaxation [31]. Second, there is an
extensive literature touting the “antioxidant” activity of
taurine (see below). According to Park et al. [32] the
activity of the sarcoplasmic reticular Ca
2+ ATPase is
inhibited by oxidative stress. It is known that sarcoplas-
mic reticular Ca
2+ uptake and Ca
2+-induced Ca
2+ release
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2+]i and modulating Ca
2+
delivery and removal from the muscle proteins. More-
over, the binding of Ca
2+ to troponin determines the
response of the muscle proteins to elevated [Ca
2+]i.
Therefore, it is not surprising that taurine is required for
normal systolic and in diastolic function.
Several other factors might also contribute to systolic
dysfunction in the taurine deficient heart. It has recently
been shown in taurine transporter knockout mice that
the phosphorylation of troponin I in the heart is signifi-
cantly elevated [30]. Because the phosphorylation of tro-
ponin I diminishes tension development by interfering
with the binding of Ca
2+ to troponin C, the taurine defi-
cient heart should generate less ventricular pressure
[33]. This conclusion is consistent with the report by
Eley et al. [34] showing that taurine deficiency is asso-
ciated with a decrease in the sensitivity of cardiac mus-
cle to Ca
2+. The work of Eley et al. [34] and Lake [35]
also show that there is a loss of myofibrils in drug-
induced taurine deficient hearts, a finding consistent
with the notion that taurine deficiency is linked to the
loss of cardiomyocytes via apoptosis [36-38].
According to Novotny et al. [15-17] taurine-depleted
cats exhibit both systolic dysfunction and a significant
increase in left ventricular diastolic chamber compliance.
This pattern is characteristic of an eccentric form of
hypertrophy, in which the myocytes become thicker and
longer than normal. However, in severe cases of
eccentric hypertrophy the ventricular chamber dilates
and the walls become thinner. Accordingly, the dilated
cardiomyopathy phase of eccentric hypertrophy is
usually associated with defects in systolic function while
the ventricular hypertrophic cardiomyopathy phase is
associated with diastolic dysfunction. Therefore, it is
reasonable to expect that diastolic defects predominate
during the initial stages of the taurine deficient cardio-
mypathy, while systolic dysfunction predominates in
severe cases of the disease. Consistent with this interpre-
tation, Schaffer et al. [36] found that rats treated with
the taurine transporter blocker, b-alanine, only develop
a mild diastolic defect characterized by impaired
removal of Ca
2+ from the cytosol and prolongation of
the contractile cycle. In contrast, systolic dysfunction is
the dominant defect in life-threatened taurine deficient
cats [12,15,16].
Taurine also appears to be essential for normal con-
traction of skeletal muscle. Warskulat et al. [39] found
that skeletal muscle function is severely impaired in
taurine transporter knockout mice. Interestingly, physi-
cal exercise decreases taurine levels of skeletal muscle,
an effect partially prevented by taurine administration
[40,41]. Administration of taurine also improves physical
endurance. In accordance with the actions of taurine in
the heart, Bakker and Berg [42] reported that the effects
of taurine are at least partially explained by an augmen-
tation in sarcoplasmic reticular Ca
2+ accumulation and
release.
Osmoregulatory activity of taurine in heart and muscle
Cells do not tolerate extreme alterations in cell size,
therefore, they possess volume regulatory mechanisms
to counteract the consequences of osmotic stress and
normalize cell volume. Changes in taurine uptake and
release contribute to the normalization of cell volume in
most cell types. In the case of heart and muscle the
turnover of taurine is normally very slow. Yet myocyte
taurine content can be dramatically altered by changes
in osmotic stress.
The identification of taurine as an osmoregulator in
the heart originated with the work of Vislie and Fugelli
[43], who studied the effect of osmotic stress in flounder
undergoing a transition from salt to fresh water. Inter-
estingly, they showed that the adaptation of flounder to
fresh water was associated with decreases in plasma
osmolality, and a corresponding decrease in myocardial
taurine content. Although the handling of taurine by the
heart was not evaluated by Vislie and Fugelli [43], Ras-
musson et al. [44] reported that isolated chick cardio-
myocytes exposed to hypoosmotic stress undergo cell
swelling, followed by a volume regulatory event that
extrudes osmolytes, such as taurine, from the cell.
In contrast to the response to hypoosmotic stress, the
regulatory response to hyperosmotic stress leads to
increased taurine influx into the cell [45]. In an attempt
to explain this phenomenon, Ito et al. [46] examined
the promoter region of the taurine transporter for
osmotic sensitive elements. They found that the promo-
ter region contains a transcriptional tonicity-responsive
element (TonE), which along with the TonE binding
protein is involved in the upregulation of the taurine
transporter in the hyperosmotically stressed
cardiomyocyte.
The osmoregulatory activity of taurine appears to be
an important determinant of cell survival. Without spe-
cifying the mechanism underlying the cytoprotection,
Han and Chesney [47,48] found that upregulation of the
taurine transporter significantly reduces the rate of
LLC-PK1 cell and renal apoptosis initiated by cisplatin.
During the process of apoptosis, apoptotic cells, such as
those treated by cisplatin, undergo an exaggerated acti-
vation of the regulatory volume decrease in which taur-
ine effluxes the cell. If the regulatory volume decrease is
disrupted by preloading the cells with taurine several
apoptotic steps, such as DNA fragmentation and apop-
totic cell shrinkage, are prevented [50]. Lang et al. [50]
found that while taurine loading did not prevent early
apoptotic events, such as caspase activation, it blocked
the progression of the apoptotic cascade beyond the cell
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proposed that Adriamycin-mediated cardiotoxicity
might be caused in part by taurine deficiency. Not only
does Adriamycin indirectly downregulate the expression
of the taurine transporter [46,51], but taurine therapy
minimizes the cardiotoxicity of Adriamycin [51,52].
Although taurine loss during apoptotis has an adverse
effect on the cell, the loss of taurine during a normal
regulatory volume decrease can benefit the hyperosmoti-
cally stressed cell by serving as a safety valve to prevent
membrane damage caused by excessive cell swelling.
This occurs in the ischemic heart, which accumulates
osmolytes, such as lactate, phosphate and sodium.
Indeed, Allo et al. [53] reported that drug-induced taur-
ine depletion reduces the taurine gradient across the cell
membrane of the ischemic heart, a factor that contri-
butes to the observed protection against ischemic injury.
Other factors contributing to the observed cytoprotec-
tion are alterations in the levels of cationic osmolytes,
such as Na
+, and activation of cytoprotective protein
kinase pathways [54,55].
While osmotic stress affects taurine transport, changes
in taurine levels can also affect the transport of other
ions through alterations in osmotic stress. One such
change occurs during pharmacological elevations in
extracellular taurine, which like cell shrinkage, enhances
Na
+-Ca
2+ exchange activity and elevates [Ca
2+]i[56].
Similarly, elevations in intracellular taurine often mimic
osmotic-mediated cell swelling. Among the transporters
that are stimulated by both cell swelling and elevations
in intracellular taurine are the fast Na
+ current and Cl
-
current [56]. Suleiman et al. [57] attributed the interac-
tion between taurine and Na
+ movement to the cotran-
sport of taurine and Na
+ via the taurine transporter.
Because hyperosmotic stress promotes the upregulation
of the taurine transporter, while a rise in intracellular
taurine simultaneously increases the osmotic load and
mass action-mediated efflux of taurine and Na
+ via the
taurine transporter, the association between the effects
of taurine and certain types of osmotic stress are pre-
dictable. In contrast, there is a poor correlation between
osmotic-mediated and taurine-mediated changes in K
+
current [56].
The link between taurine and Cl
- current is intriguing,
as the most widely distributed Cl
- channel, known as
the anion organic osmolyte channel, also conducts taur-
ine [58]. Moreover, a member of the FXYD family of
small membrane-spanning proteins, known as phospho-
lemman, forms volume-sensitive channels that conduct
anions, such as Cl
-,a sw e l la st h ez w i t t e r i o n ,t a u r i n e
[59]. Because phospholemman is regulated by protein
kinases involved in regulatory volume changes, it has
been implicated in cell swelling of cardiomyocytes sub-
jected to hypoosmotic challenges. Indeed, reductions in
phospholemman expression decrease taurine efflux in
astrocytes [60]. However, cardiomyocytes obtained from
phospholemman knockout mice swell to the same
extent as wild-type mice in response to a hypoosmotic
challenge [61]. Moreover, mouse cardiomyocytes do not
undergo a characteristic regulatory volume decrease,
raising the possibility that phospholemman may only
p l a yas u b t l er o l ei nv o l u m er e g u l a t i o n .N o n e t h e l e s s ,
phospholemman is closely tied to transporters involved
in osmotic regulation. Jia et al. [62] found that the heart
of phospholemman knockout mice exhibit reductions in
Na
+-K
+ ATPase activity and increases in ejection frac-
tion. In contrast, overexpression of phospholemman
increases contractility and elevates [Ca
2+]i, effects attrib-
uted to inhibition of the Na
+/Ca
2+ exchanger [63,64].
Thus, there are still many unresolved questions regard-
ing the role of regulatory volume processes and the
osmoregulatory actions of taurine in the heart.
Conjugation reactions of taurine in the heart and skeletal
muscle
Taurine is involved in several conjugation reactions, with
the most common reactions occurring in the liver. None-
theless, one of the most important conjugation reactions
takes place in the mitochondria of extrahepatic cells and
has a major impact on mitochondrial function [6,8]. The
formation of 5-taurinomethyl uridine in the anticodon
wobble position of mitochondrial tRNA
Leu(UUR) increases
UUG translation although the translation of UUA is
unaffected [7]. A direct cause-effect relationship between
a deficiency in 5-taurinomethyluridine and mitochondrial
diseases has been proposed but not definitively estab-
lished. A major complication is that patients with symp-
toms of myopathy, encephalopathy, lactic acidosis and
stroke-like episodes contain several mutations, only one
resulting in a reduction in 5-taurinomethyluridine con-
tent [5]. Based on the potential role of 5-taurinomethy-
luridine in modulating mitochondrial protein synthesis,
Schaffer et al. [8] proposed a mechanism for the regula-
tion of reactive oxygen species production by taurine.
They predict that diminished rates of 5-taurinomethyluri-
dine arising from taurine deficiency reduce the expres-
sion of mitochondrial encoded proteins. Because these
proteins are functional subunits of respiratory chain
complexes, reduced expression invariably decrease the
activity of the complexes. As flux of electrons through
the respiratory chain diminishes, there is a risk that elec-
trons will be diverted from the electron transport chain
to other acceptors, such as oxygen. The major source of
electrons involved in mitochondrial ROS generation
comes from complexes 1 and 3 [65]. By elevating the
expression of mitochondrial encoded proteins, taurine
ensures a smooth coupling between the delivery of redu-
cing equivalents into the electron transport chain, flux of
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ATP production by oxidative phosphorylation.
Can intracellular taurine provide protection against
oxidative stress?
The literature is awash with studies claiming that taur-
ine is an “antioxidant.” Yet Arouma et al. [66] have
clearly shown that taurine is incapable of directly
scavenging the classical reactive oxygen species (ROS).
The only reactive species that is directly neutralized by
taurine is HOCl, which is converted to N-chlorotaurine
[4]. Because N-chlorotaurine is less toxic than HOCl,
the neutralization of HOCl by taurine might limit myo-
cardial damage caused by neutrophils [4]. This led to
the suggestion that the formation of N-chlorotaurine
might be the most important antioxidant activity of
taurine [67]. However, recent studies have uncovered a
key action of taurine could regulate the rate of ROS
generation by the mitochondria [8]. This is important
because elevated superoxide generation by the mito-
chondria is capable of initiating the mitochondrial per-
meability transition, which in turn triggers the apoptotic
cascade [68].
Most of the studies that ascribe an antioxidant activity
to taurine utilize pharmacological levels of the b-amino
acid to minimize oxidative damage. Only a few studies
have examined the potentiation of oxidative damage by
taurine depletion. In one such study, Harada et al. [52]
showed that drug-induced taurine deficiency potentiates
Adriamycin-induced oxidative stress in the heart, an
effect thought to exacerbate the cardiotoxicity of Adria-
mycin. In a related study, Schaffer et al. [69] found that
drug-induced taurine deficiency enhances angiotensin
II-mediated apoptosis. Although Schaffer et al. [69] did
not evaluate the effect of taurine deficiency on angioten-
sin II-mediated oxidative damage, Ricci et al. [68]
recently found that angiotensin II-mediated apoptosis is
largely caused by increased oxidative damage within the
mitochondria. These two studies revealing an adverse
effect of taurine depletion are seemingly at odds with a
study that uncovered a beneficial effect of taurine defi-
ciency against ischemia [53]. However, this apparent
contradiction merely emphasizes the multifaceted
actions of taurine. While the antioxidant activity of taur-
ine might benefit the hypoxic cardiomyocyte, the domi-
nant effects of taurine depletion are diminished Na
+ and
Ca
2+ overload and stimulation of the PI 3-kinase/Akt
signaling pathway [54,55,70,71].
Role of taurine in membrane stabilization
In 1973 Huxtable and Bressler [72] found that incubation
of isolated sarcoplasmic reticulum with phospholipase C
damaged the membrane, leading to reductions in Ca
2+
transport and ATPase activity that were diminished by
addition of taurine to the medium. This observation led
the authors to propose that taurine acts as a membrane
stabilizer. It was subsequently shown that taurine directly
interacts with membranes, presumably by forming an
electrostatic interaction between the amino and sulfonic
acid groups of taurine and the phosphate and amino or
quaternary ammonium groups of the phospholipids,
respectively [73]. This interaction appears to cause minor
changes in the lipid bilayer, allowing more calcium to
bind to the phospholipids [74]. However, based on elec-
tron spin resonance, neither polymorphic phase changes
nor fluidity changes are induced in the lipid bilayer fol-
lowing acute exposure of isolated membranes with taur-
ine. This led to further characterization of the
membrane-linked actions of taurine. One of the most
prominent taurine-mediated changes in membrane func-
tion was found to be the inhibition of phospholipid
N-methyltransferase, an enzyme that catalyzes the con-
version of phosphatidylethanolamine (PE) to phosphati-
dylcholine (PC) [75]. This reaction is important because
taurine levels regulate the ethanolamine:choline ratio of
some membranes [76]. In the biological membrane, PE is
preferentially localized to the outer membrane leaflet
where it assumes a bilayer structure while PC is a hexa-
gonal former and is preferentially localized to the inner
leaflet of the membrane. Thus, changes in the PE/PC
ratio have a dramatic influence on the structure of biolo-
gical membranes, which in turn alters both membrane
fluidity and the activity of membrane enzymes and trans-
porters [73].
Are taurine-mediated alterations in protein
phosphorylation important physiological functions in
heart and skeletal muscle?
T h ei d e at h a tt a u r i n ei sc a p a ble of altering the phos-
phorylation of key proteins was initially demonstrated in
hearts and retina of taurine treated and drug-induced
taurine depleted rats [77]. In the heart, the taurine-
dependent phosphorylation of a 44 kDa protein is pro-
moted by reductions in taurine levels but diminished by
taurine treatment. The effect of taurine depletion on the
44 kDa protein, which was subsequently identified as
pyruvate dehydrogenase, is consistent with the metabolic
changes mediated by drug-mediated taurine depletion of
rat heart [78]. In accordance with the known inhibition
of pyruvate dehydrogenase by protein phosphorylation,
Mozaffari et al. [78] found that taurine depletion led to
a significant elevation of lactate and pyruvate production
despite the reduction in pyruvate utilization by the citric
acid cycle. The enzyme involved in the phosphorylation
of pyruvate dehydrogenase in the taurine deficient heart
was not identified, but the response to inhibitors ruled
out any involvement of cAMP and cGMP dependent
protein kinases [79].
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gulatory activity of taurine. According to Liu et al. [80]
hypoosmotic stress promotes the translocation of selec-
tive protein kinase C isoforms (PKCa, PKCε, and PKCζ)
to specific membranes, an event associated with their
activation. Interestingly, taurine treatment also leads to
the activation of the same three protein kinase C iso-
forms [81]. The activation of these same protein kinase
C isoforms contributes to the osmoregulatory actions of
taurine by activating a signaling pathway in which an
early event is the stimulation of NADPH oxidase. In the
hypoosmotically stressed cell, NADPH oxidase-derived
ROS inhibits protein tyrosine phosphatase 1B, which
potentiates swelling-induced taurine release [82,83].
Tyrosine kinases represent another group of protein
kinases that are regulated by osmotic stress. Following a
hypoosmotic insult, tyrosine kinases activate a down-
stream target, PI 3-kinase, whose activation stimulates
the phosphorylation of Akt [84]. Upregulation of the PI
3-kinase/Akt pathway is cytoprotective, rendering the
cell resistant to pathological insults, such as hypoxia,
osmotic imbalances, energy deficiency and cationic over-
load. Drug-induced taurine deficiency also leads to the
activation of the PI 3-kinase/Akt pathway, rendering the
cell resistant to hypoxia-mediated cell death [54].
Although the beneficial effect of taurine depletion
against hypoxic injury has been attributed to diminished
accumulation of Na
+ and Ca
2+[55,57], the stimulation of
protein kinase-linked cytoprotective pathways, such as
the PI 3-kinase/Akt pathway and PKCε associated cyto-
protective pathways, are also likely candidates for the
cytoprotection. Because the effects of taurine depletion
resemble the potent cytoprotective procedure referred
to as ischemic preconditioning [53,54,71], the protein
kinase-linked pathways warrant further consideration.
Recent studies reveal that the phosphorylation state of
two proteins involved in excitation-contraction coupling
is affected by taurine depletion (see section on contrac-
tile function). However, the protein kinases affecting
these phosphoproteins as well as the importance of
these phosphorylation changes in the taurine transporter
knockout mice remain to be determined.
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